Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En enkeltarmsundersøgelse, der evaluerer effektiviteten og sikkerheden af ​​EVX-01 i kombination med Pembrolizumab hos voksne med uoperabelt eller metastatisk melanom

3. november 2026 opdateret af: Evaxion Biotech A/S

Et åbent, enkeltarmsforsøg, der evaluerer effektiviteten og sikkerheden af ​​EVX-01 i kombination med Pembrolizumab i checkpoint-hæmmerbehandlingsnaive voksne med uoperabelt eller metastatisk melanom

The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

Patients will initiate treatment with pembrolizumab at the start of the trial and receive up to 18 treatment cycles (approximately 2 years). Immunization with the EVX-01 will be initiated at Week 12. In total, 10 doses of EVX-01 will be administered intramuscularly, with 6 doses given two weeks apart and 4 booster doses at later time points.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

17

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Wollstonecraft, New South Wales, Australien, 2065
        • Melanoma Institute Australia
    • Western Australia
      • Nedlands, Western Australia, Australien, 6009
        • One Clinical Research
    • Italy
      • Milan, Italy, Italien
        • Divisione di Oncologia Medica del Melanoma
      • Naples, Italy, Italien
        • Instituto Nazionale Tumori IRCCS Fondazione

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Be at least 18 years of age on day of signing informed consent.

  • Histologically confirmed, and not amenable to local therapy, metastatic or unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system.

    1. Patient may not have a diagnosis of uveal or ocular melanoma.
    2. Patients must be treatment naïve to checkpoint inhibitor (CPI) therapy
    3. Patients must have testing for a BRAF mutation prior to study entry.

Note: Patients with BRAF V600E mutant melanoma may have received prior BRAF inhibitor therapy as first-line systemic therapy and be eligible for this study as second line treatment. At the discretion of the investigator, patients with BRAF V600E mutant melanoma who have NOT received a BRAF inhibitor are also eligible for this study as first line treatment if they meet the following additional criteria:

i. LDH < local ULN, ii. No clinically significant tumor related symptoms in the judgment of the investigator, and iii. Absence of rapidly progressing metastatic melanoma in the judgment of the investigator

  • Have measurable disease per RECIST 1.1 as assessed by the local site investigator within 4 weeks prior to the first visit. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Patients must be willing and able to provide fresh or frozen tumor tissue from an unresectable or metastatic site of disease for neoepitope and biomarker analyses. If a sufficient amount of tumor tissue from an unresectable or metastatic site is not available prior to the start of the screening phase, subjects must consent to allow the acquisition of additional tumor tissue. In addition, participants may provide additional biopsy at the time of discontinuation due to progression.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
  • Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
  • Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: EVX-01 in combination with pembrolizumab

EVX-01 is administered im. Pembrolizumab is administered according to label

Investigational drug given in combination with standard of care

Standard of care

Andre navne:
  • Keytruda

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in the best overall response (BOR)
Tidsramme: Measurements at Baseline through study completion (up to 102 weeks)

Composite of a BOR of complete response (CR) or PR for patients with SD at the time of first EVX-01 administration and a BOR of CR for patients with PR at the time of first EVX-01 administration, within 2 years of treatment with pembrolizumab, as per RECIST 1.1 criteria

Measurements at Baseline through study completion (up to 102 weeks)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in overall response rate
Tidsramme: Measurements at Baseline through study completion (up to 102 weeks)

Overall response rate, defined as the proportion of the patients who have best response as CR or PR assessed 2 years after initiation of treatment with pembrolizumab, as per RECIST 1.1 criteria

Measurements at Baseline through study completion (up to 102 weeks)
Change in progression free survival (PFS)
Tidsramme: Measurements at Baseline through study completion (up to 102 weeks)

PFS in patients with an assessment of SD, PR, or CR at the time of first EVX-01 administration, assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from the first EVX-01 administration to the first documented disease progression per RECIST 1.1. criteria or death due to any causes, whichever occurs first

Measurements at Baseline through study completion (up to 102 weeks)
Change in overall survival (OS)
Tidsramme: Measurements at Baseline through study completion (up to 102 weeks)

OS assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from initiation of treatment of pembrolizumab to death due to any cause

Measurements at Baseline through study completion (up to 102 weeks)
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: Measurements at Baseline through study completion (up to 102 weeks)

Number, type and severity of adverse events (AEs) and serious adverse events (SAEs)

Measurements at Baseline through study completion (up to 102 weeks)
Immunologic response induced by EVX-01
Tidsramme: Measurements at Baseline through study completion (up to 102 weeks)

Activation and level of neoepitope specific T-cells before, during and after EVX-01 immunization

Measurements at Baseline through study completion (up to 102 weeks)
Percentage of patients in which EVX-01 is generated, produced, and administered
Tidsramme: From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)

Percentage of patients in which EVX-01 is generated, produced, and administered

From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. september 2022

Primær færdiggørelse (Faktiske)

7. april 2026

Studieafslutning (Faktiske)

7. april 2026

Datoer for studieregistrering

Først indsendt

22. marts 2022

Først indsendt, der opfyldte QC-kriterier

1. april 2022

Først opslået (Faktiske)

4. april 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner